The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Hodgkin lymphoma: exciting data at EHA and ASH 2019
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, talks us through the key Hodgkin lymphoma data that was presented at EHA 2019, and any data to watch out for at this year’s ASH meeting at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Brockelmann specifically mentions the HD16 trial investigating radiotherapy consolidation therapy for the treatment of Hodgkin lymphoma, and the use of brentuximab vedotin in combination with nivolumab in pediatric and adolescent patients.
